
    
      This is a multicenter study in adult patients with AF and ESRD who are on hemodialysis and
      who have stroke risk factors making them candidates for oral anticoagulation. Patients will
      be randomized to apixaban versus warfarin, and will be treated for up to 15 months.
    
  